- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02002468
Follow-up of Abnormal and Inadequate Smear-test Results
Follow-up of Abnormal and Inadequate Test Results in the Danish Cervical Cancer Screening Program.
Denmark has a higher incidence of cervical cancer than other Nordic countries, although all Danish women (aged 23-65) are screened regularly to identify possible cervical dysplasia or asymptomatic invasive cancer.
Annually 40 000 women receives an abnormal or inadequate test result and a follow-up recommendation.
However problems with delayed follow-up may threaten the effectiveness of the Danish Cervical Cancer Screening Program, as 20% of women are delayed and dysplasia potentially can progress into cancer.
Delayed follow-up is found in situations where women either consciously or unconsciously postpone follow-up, or because of organizational aspects of the screening program, where communication regarding test results can fail either in content or with delay.This study will evaluate two interventions designed to increase follow-up:
- A letter with the test result and potential recommendation for follow up will be sent to the women (RCT). The intention is to ensure that all women will be notified about the test result, quickly, homogenously and in layman's written language, still with the opportunity to contact or be contacted by the general practitioner, if there is special needs. Furthermore, it is assumed that general practitioner consultations regarding delivery of normal test results will decrease, so that cost savings is a potential side benefit
- Electronic reminder to the general practitioner if women have not had the recommended follow up, giving the general practioner´s an opportunity to remind the women (retro perspective cohort study).
The results will be of great importance to the future organisation of cervical and colorectal cancer screening programmes in Denmark, but will also have international interest because of their similar challenges.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Central Denmark Region
-
Aarhus, Central Denmark Region, Danmark, 8000
- University of Aarhus
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- woman with a pap-smear test
Exclusion Criteria:
- less than 23 years
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Test result sent by letter
The pap-smear test result is sent by letter directly to the women.
Women in need of follow up are in the letter recommended to contact their general practitioner.
|
|
|
Aktiv komparator: Test result conveyed by general practitioners
In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of women with timely follow-up
Tidsramme: 1½ year
|
The proportion of women followed up will be calculated as cumulated incidence proportions according to four timeframes (undesirable early, as recommended, late, very late), and be compared by relative risks.
The results will be presented in totals and separately depending on the test result (normal/inadequate/Bethesda classification 2001/HPV).
|
1½ year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency of general practitioner contacts (consultations/telephone calls /e-mails) regarding conveying the smear test result.
Tidsramme: Three months after the smear test.
|
The two randomisation groups will be compared with respect to contacts with general practitioner after the smear test the first days, weeks, months after the general practitioner is notified of the screening result.
|
Three months after the smear test.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Peter Vedsted, Center for Research in Cancer Diagnosis in Primary Care - (CaP), Aarhus University
- Studieleder: Flemming Bro, The Research Unit of General Practice in Aarhus, Aarhus University
- Studieleder: Berit S Andersen, The Department of Public Health Programmes at Regional Hospital Randers
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Cervix cancer screening
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Carcinom in situ af livmoderhalsen
-
Mithra PharmaceuticalsAfsluttetCervix intraepitelial neoplasi | Uterin cervikal neoplasiBelgien
-
Liao NingRekrutteringBrystneoplasmerKina
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteAfsluttetRectal Neoplasma Carcinoma in Situ AdenocarcinomaCanada
-
SamanTree Medical SASt. Vincenz Krankenhaus GmbH, PaderbornAfsluttetBrystbevarende kirurgi | Brystkræft - Ductal Carcinoma in Situ (DCIS)Tyskland
-
University of AarhusAfsluttetCervikal dysplasi | Cervikal læsion | Cervix sygdomDanmark
-
Elizabeth J FranzmannAveta Biomics, Inc.RekrutteringOrofaryngeal dysplasi | Mundhule dysplasi | Oral carcinoma in situForenede Stater
-
Fondazione del Piemonte per l'OncologiaRekrutteringBrystkræft | Brystkræft - Ductal Carcinoma in Situ (DCIS)Italien
-
Barretos Cancer HospitalAfsluttetCervikal intraepitelial neoplasi | Cervix NeoplasmaBrasilien
-
The First Affiliated Hospital of Henan University...Ikke rekrutterer endnuEsophageal Carcinoma in Situ AJCC V7
-
Catholic University of the Sacred HeartRekrutteringOral Lichen Planus | Oral karcinom | Oral carcinoma in situItalien
Kliniske forsøg med Test result sent by letter
-
Lokman Hekim ÜniversitesiRekrutteringRespiratorisk insufficiens | Duchennes muskeldystrofi | Spinal muskelatrofi | Nedsat åndedrætsfunktion | Neuromuskulære sygdomme hos børn | PlethysmografiKalkun
-
Cari Health Inc.Samplimy Medical ABRekrutteringSmerte, kronisk | Metabolisme Medicin toksicitet | Metadon toksicitet | Metadon overdosis | Lægemiddelmetabolisme, dårlig, CYP2D6-relateretForenede Stater
-
Dar El Oyoun HospitalUkendtGrå stær | Bivirkningshændelse | MydriasisEgypten
-
Hospital 9 de Julio de Las BreñasInstituto de Cardiología de CorrientesRekrutteringArvelig amyloidose, transthyretin-relateretArgentina